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Introduction
Familial Mediterranean fever (FMF) is associated with
variations in the MEFV gene resulting in proteolytic
activation of IL-1b through the inflammasome complex.
There is no established treatment available for those resis-
tant or intolerant to standard of care colchicine treatment.
Canakinumab, a fully human selective anti-IL-1b mono-
clonal antibody with a half-life of ~4-weeks binds to
human IL-1b and neutralizes its proinflammatory effects.
Objectives
To evaluate the efficacy and safety of canakinumab in
adolescents and adults with FMF who are resistant or
intolerant to colchicine.
Methods
FMF patients with ≥1 attack/month in the preceding
3-months despite the highest tolerated colchicine dose
were eligible to enter a 30-day run-in period. Those with
an attack in the run-in period advanced to a 3-month
treatment period to receive canakinumab 150mg sc every
4-weeks starting at the next attack in the following
month. Patients then followed-up for up to 2 months or
until the next attack. Attacks were confirmed by presence
of fever, serositis, and elevated CRP. Primary efficacy out-
come was the proportion of patients with ≥50% reduction
in time-adjusted attack frequency in the treatment vs
pre-treatment periods. Secondary objectives included
the percent of patients with no attacks in the treatment
period, time to next attack after the last canakinumab
dose, and changes in the quality of life by SF-36. Safety
was assessed by AEs and laboratory values at each visit.
Results
Thirteen patients enrolled in the run-in and 9 (median
age 22 yrs, range 12-34 yrs) entered treatment periods.
Only 1 patient had an attack (peritonitis) during the
treatment period and all had a ≥50% reduction in their
time-adjusted pre-treatment attack rate. Median baseline
elevated CRP (58mg/L) and serum AA (162mg/L) levels
normalized (CRP, 2.5mg/L; SAA, 5.8mg/L) by Day 8
and remained low throughout the study. The Physical
and Mental Component scores of the SF-36 improved
from a median baseline of 32 and 38 to 81 and 78 at
Day 8 respectively, and continued to improve throughout
the treatment period. Five patients had an attack in the
follow-up period, which occurred a median 71 days
(31-78 days) from the last canakinumab dose. Compared
to baseline, the physician and patient global assessment
of FMF control improved with treatment with overall the
response to treatment reported as Very Good by both
physicians (9/9) and patients (7/9) at study end. Eight
patients reported at least one adverse event (AE) with
headache (n=4) and upper respiratory tract infection
(n=2) being the only AEs reported in more than 1
patient. No one discontinued early from the trial.
Conclusion
In this pilot study, canakinumab was found to be effective
at controlling the attack recurrence in FMF patients resis-
tant or intolerant to colchicine. AEs were similar to pre-
vious canakinumab trials and were managable. Further
studies are warranted to explore the role of canakinumab
in the treatment of FMF.
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